Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. (SNY)

Sanofi-Aventis S.A. (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,741,256
  • Shares Outstanding, K 2,504,138
  • Annual Sales, $ 42,135 M
  • Annual Income, $ 5,101 M
  • 60-Month Beta 0.60
  • Price/Sales 2.87
  • Price/Cash Flow 8.94
  • Price/Book 1.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.91
  • Number of Estimates 2
  • High Estimate 0.98
  • Low Estimate 0.83
  • Prior Year 0.63
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.92 +2.38%
on 11/14/19
47.47 -3.12%
on 10/30/19
-0.18 (-0.39%)
since 10/18/19
3-Month
42.45 +8.34%
on 08/23/19
47.47 -3.12%
on 10/30/19
+3.39 (+7.96%)
since 08/20/19
52-Week
40.00 +14.98%
on 08/05/19
47.47 -3.12%
on 10/30/19
+1.32 (+2.96%)
since 11/20/18

Most Recent Stories

More News
Protalix Finalizes Accelerated Approval Pathway for PRX-102

Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

SNY : 45.89 (-0.71%)
ALKS : 20.33 (+1.90%)
BDSI : 6.22 (+1.14%)
PLX : 0.23 (-4.17%)
Cancer Drugs Poised to Improve as New Developments Help Previous Therapies Target Better

USA News Group - A stunning revelation came back in April, when an Oxford published study pointed to only 3% of the cancer drugs tested between 2000 and 2015 were approved to treat patients, whereas another...

ONCY : 0.94 (+5.62%)
ONC.TO : 1.24 (+5.98%)
SRNE : 1.56 (+2.63%)
AZN : 47.10 (-1.20%)
BNTX : 21.60 (+6.25%)
SNY : 45.89 (-0.71%)
The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's

The Zacks Analyst Blog Highlights: Chevron, HSBC, Sanofi, Sony and Moody's

MCO : 224.88 (+0.45%)
SNY : 45.89 (-0.71%)
SNE : 61.60 (-0.48%)
HSBC : 37.19 (-0.67%)
CVX : 117.81 (+1.17%)
Top Stock Reports for Chevron, HSBC & Sanofi

Top Stock Reports for Chevron, HSBC & Sanofi

SNY : 45.89 (-0.71%)
SNE : 61.60 (-0.48%)
MCO : 224.88 (+0.45%)
HSBC : 37.19 (-0.67%)
CVX : 117.81 (+1.17%)
AON : 200.00 (+0.19%)
Amarin (AMRN) Gets FDA Panel Nod for Vascepa Label Expansion

Amarin (AMRN) gets favorable FDA Advisory Committee vote to expand the label of Vascepa capsules to reduce cardiovascular risk in patients with persistent elevated triglycerides.

SNY : 45.89 (-0.71%)
AMRN : 20.05 (-11.79%)
AMGN : 225.80 (+0.58%)
ANIK : 60.35 (+0.37%)
Glaxo's Nucala Meets Goal in Rare Inflammatory Disorder Study

GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.

SNY : 45.89 (-0.71%)
GSK : 43.93 (-1.28%)
AZN : 47.10 (-1.20%)
REGN : 346.86 (+0.70%)
Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

AZN : 47.10 (-1.20%)
SNY : 45.89 (-0.71%)
REGN : 346.86 (+0.70%)
INO : 2.49 (+5.06%)
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

NVO : 54.65 (-4.19%)
NVS : 90.57 (+0.19%)
SNY : 45.89 (-0.71%)
AGN : 184.54 (-0.37%)
JNJ : 135.08 (+0.19%)
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

BMY : 55.87 (-1.08%)
SNY : 45.89 (-0.71%)
JNJ : 135.08 (+0.19%)
AGN : 184.54 (-0.37%)
AZN : 47.10 (-1.20%)
NVS : 90.57 (+0.19%)
NVO : 54.65 (-4.19%)
Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales

Emergent (EBS) rides high on both earnings and revenues beat in the third quarter. ACAM2000 and Narcan drive revenues.

SNY : 45.89 (-0.71%)
GSK : 43.93 (-1.28%)
EBS : 53.99 (-0.22%)
ANIK : 60.35 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade SNY with:

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Key Turning Points

2nd Resistance Point 46.68
1st Resistance Point 46.45
Last Price 45.89
1st Support Level 45.96
2nd Support Level 45.71

See More

52-Week High 47.47
Last Price 45.89
Fibonacci 61.8% 44.62
Fibonacci 50% 43.74
Fibonacci 38.2% 42.85
52-Week Low 40.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar